Drug intelligence / Profile preview

C010DS-Zn

Development stage: Preclinical
Lead developer: Xylonix IP Holdings
Modality: Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

C010DS-Zn is a degradable ligand-modified biopolymer-based zinc (II) complex being developed by IP Holdings in collaboration with Duke-NUS and Xylonix. It acts as a PARP1 agonist and a novel immunotherapy designed to normalize macrophage immunity by targeting immunosuppressive M2-like macrophages. In oncology, the compound induces parthanatos, a form of programmed cell death, through the hyperactivation of PARP1. Beyond cancer, C010DS-Zn is being investigated for its potential to reduce macrophage-mediated inflammation at lower doses, with applications in long COVID complications such as thrombosis, lupus, and heart failure.

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on C010DS-Zn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C010DS-Zn.

Explore the full profile